查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
过度活跃的膀胱治疗(OAB)市场：按类型(抗胆碱能药物、肉毒桿菌毒素、神经调节)、疾病类型(特发性 OAB、神经性 OAB)、地区世界预测至2027
市场调查报告书
商品编码
1099211

过度活跃的膀胱治疗(OAB)市场：按类型(抗胆碱能药物、肉毒桿菌毒素、神经调节)、疾病类型(特发性 OAB、神经性 OAB)、地区世界预测至2027

Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 203 Pages | 订单完成后即时交付

价格
简介目录

全球膀胱过度活动症治疗市场预计将从 2022 年的 35 亿美元增长到 2027 年的 42 亿美元，预测期内的复合年增长率为 3.6%。

全球膀胱过度活动症患病率的增加以及对可用治疗方案的认识不断提高正在推动市场增长。此外，预计在OAB治疗中使用神经调节技术会产生更大的积极作用。

“2021 年膀胱过度活动症(OAB)治疗市场由 Mirabeglon 细分市场主导”

膀胱过度活动症治疗市场按类型分为抗胆碱能药物、米拉贝隆、肉毒桿菌毒素、神经调节和其他治疗。与市场上可用的其他药物类别相比，米拉贝隆将在 2021 年占据压倒性的市场份额，因为其与该药物相关的副作用更少。此外，随着为 OAB 引入新的 SNM 和 PTNS，预计神经分割空间将以更快的速度增长。

“特发性膀胱过度活动症将在预测区间内实现膀胱过度活动症药物市场的最高增长”

膀胱过度活动症治疗市场根据疾病类型分为特发性膀胱过度活动症和神经源性膀胱过度活动症。由于特发性膀胱过度活动症的高发病率和治疗药物的使用增加，特发性膀胱过度活动症占据了更大的市场份额。

“2021年北美将占据压倒性份额”

膀胱过度活动症 (OAB) 治疗市场在地理上分为北美、欧洲、亚太地区、拉丁美洲和中东/非洲。到 2021 年，北美将在 OAB 治疗市场占有主要份额。北美拥有导致该地区 OAB 治疗市场成熟的大部分主要市场参与者。此外，美国有利的赎回政策是北美市场增长的主要预测因素之一。

本报告中进行的主要访谈分类如下

  • 按公司类型：供应方：80.0%，需求方：20.0%
  • 按职称：经理：45.0%，CXO 和董事：30.0%，高管：25.0%
  • 按地区划分：北美：55%，欧洲：20%，亚太地区：10%，拉丁美洲：10%，中东和非洲：5%

本报告中公布的公司简介列表

    • Astellas Pharma Inc. (Japan)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Pfizer Inc. (US)
    • Abbvie Inc. (US)
    • Viatris Inc. (US)
    • Hisamitsu Pharmaceutical Co., Inc. (Japan)
    • Johnson & Johnson Services, Inc. (US)
    • Endo Pharmaceuticals Inc. (Ireland)
    • Lupin (India)
    • Amneal Pharmaceuticals Llc (US)
    • Sun Pharmaceutical Industries Ltd. (India)
    • Glenmark (India)
    • Macleods Pharmaceuticals Ltd (India)
    • Medtronic (Ireland)
    • Ajanta Pharma (India)
    • Granules India Limited (India)
    • Urovant Sciences (US)
    • Apotex Inc. (Canada)
    • Laborie (US)
    • Intas Pharmaceuticals Ltd. (India)
    • Bayer Ag (Germany)
    • Medytox (South Korea)
    • Altherx Pharmaceuticals (US)
    • Taiho Pharmaceutical Co., Ltd. (Japan)
    • Hugel, Inc. (South Korea)

调查目标

本报告详细介绍了全球膀胱过度活动症治疗市场。它旨在估计类型、疾病类型和地区等不同细分市场的市场规模和未来增长潜力。我们还分析了影响市场增长的因素(促进因素、市场製约因素、机会等)。它评估利益相关者的市场机会，并为市场领导者提供竞争格局的详细资讯。我们还在调查细胞分析市场对整个微型市场的增长趋势、前景和贡献。该报告预测了四个关键地区的细分市场收入。

购买报告的原因

本报告提供以下几点见解

  • 市场渗透。细胞分析市场中 25 家顶级公司提供的有关细胞分析的综合信息。这是一份按类型、疾病类型和地区分析膀胱过度活动症治疗市场的报告。
  • 新兴市场市场。有关有利新兴市场的综合信息。我们正在按主要地区分析各种细胞分析的市场。
  • 市场多元化。有关新产品、未开发领域、膀胱过度活动症 (OAB) 治疗市场的最新发展和投资的综合信息。
  • 竞争评估。详细评估主要公司在膀胱过度活动症治疗市场的市场排名和策略。

目录

第 1 章介绍

  • 研究目的
  • 市场定义
    • 包含与排除
  • 市场范围
    • 目标市场
    • 考虑的年份
  • 货币
  • 限制
  • 利益相关者
  • 变更摘要

第 2 章调查方法

  • 调查方法
    • 初步调查
    • 自上而下和自下而上的方法
  • 数据三角法
    • 二次调查
    • COVID-19 特定假设
  • 调查限制
  • 风险评估
  • 增长率假设/增长预测
    • 供给侧
    • 需求方
      • 来自主要专家的见解

第 3 章执行摘要

第 4 章重要考虑

  • 膀胱过度活跃症市场概况
  • 亚太地区：按类型和国家/地区分列的膀胱过度活动症治疗市场份额(2021 年)
  • 2022 年与 2027 年按疾病类型分列的膀胱过度活动症治疗市场份额
  • 过度活跃的膀胱治疗市场：地理增长机会的机会

第 5 章市场概述

  • 简介
  • 市场动态
    • 市场促进因素
      • 膀胱过度活动症的患病率增加
      • 人口迅速老龄化，随后以 OAB 为特征的疾病发病率增加
      • 创新膀胱内疗法的开发和使用
      • 未来几年不断增加的研发投资和新疗法的推出
    • 市场抑制因素
      • 频繁的产品召回
      • 抗胆碱能药物的副作用增加
    • 市场机会
      • 针对特定药物的新疗法、强大的管道和专利悬崖
    • 市场挑战
      • 社会污名和缺乏对 OAB 的认识
  • 不确定性对膀胱过度活动症治疗市场的影响
  • COVID-19 对膀胱过度活动症治疗市场的影响
  • 影响客户业务的趋势/动盪
  • 价值链分析
  • 供应链分析
  • 生态系统分析
  • 监管场景
    • 医药行业
      • 监管要求
        • 欧盟法规
        • 美国法规
    • 医疗器械行业
      • 监管要求
        • 欧盟法规
        • 美国法规
  • 技术分析
  • 2022-2023年主要会议和活动
  • 专利分析
  • 波特五力分析
    • 来自新进入者的威胁
    • 来自替代品的威胁
    • 买方的议价能力
    • 供应商的议价能力
    • 竞技比赛
  • 价格分析
  • 主要利益相关者和采购标准
  • 管道分析

第 6 章过度活跃的膀胱治疗市场：按类型

  • 简介
  • 米拉贝格隆
    • 与抗胆碱能药物相比，副作用更少可能推动该细分市场的增长
  • 抗胆碱药
    • 索利那新
      • Solifenacin 在减少尿失禁频率方面比其他抗胆碱能药物更有效——这是推动市场增长的关键因素
    • 奥昔布宁
      • Oxybutynin 是 OAB 市场上处方最广泛的抗胆碱能药物。
    • 非索罗定
      • 非索罗定对逼尿肌中的毒蕈碱乙□胆碱受体具有抗毒蕈碱作用，导致膀胱收缩减少。
    • 达非那新
      • Darifenacin 成本高于其他抗胆碱能药物，可能在一定程度上减缓市场增长
    • 托特罗定
      • 托特罗定是OAB中的第三种处方药，因为它副作用少且具有长期的临床益处。
    • Trospium
      • Trospium 与口干的发生率低有关，因此停药率相对较低。
    • 其他抗胆碱能药物
  • 肉毒桿菌
    • 肉毒桿菌毒素比抗胆碱能药物更有效，使其成为一种流行的治疗选择
  • 神经修饰
    • 越来越多地采用神经调节来治疗膀胱过度活动症，以促进该细分市场的增长
  • 其他治疗

第 7 章过度活跃的膀胱治疗市场：按疾病类型

  • 简介
  • 特发性膀胱过度活动症
    • 可报销用于治疗特发性 OAB 的药物以促进该市场的增长
  • 神经性膀胱过度活动症综合征
    • 帕金森病
      • 增加使用抗胆碱能和β-肾上腺素能激动剂治疗帕金森病以促进市场增长
    • 中风
      • 脑卒中患病率增加，OAB 发病率增加，OAB 治疗需求增加
    • 多发性硬化症
      • 优惠的报销政策支持 MS 的 OAB 治疗市场的增长
    • 脊髓损伤
      • SCI 中膀胱过度活动症的高患病率促进了神经源性膀胱过度活动症治疗市场的增长
    • 其他障碍

第 8 章过度活跃的膀胱治疗市场：按地区划分

  • 简介
  • 北美
    • 美国
      • 优惠的报销政策使美国成为膀胱多动症治疗的最大市场
    • 加拿大
      • BOTOX 治疗膀胱过度活动症并推动加拿大市场增长的使用和需求增加
  • 欧洲
    • 德国
      • 老龄化和 OAB 的高患病率，尤其是女性，预计将增加德国的目标患者群体。
    • 英国
      • 在英国开展的旨在推动 OAB 市场增长的举措和宣传活动
    • 法国
      • 与其他国家相比，法国的低还款率可能会在一定程度上限制市场增长
    • 意大利
      • 意大利製药业有望为 OAB 製药公司提供有利的增长机会。
    • 西班牙
      • 西班牙的人口结构变化和 OAB 的高患病率为膀胱过度活动症治疗市场提供了重要的增长机会
    • 其他欧洲
  • 亚太地区
    • 日本
      • 治疗方案的进步推动日本市场的增长
    • 中国
      • 越来越多地采用 BOTOX 治疗 OAB 使中国成为一个利润丰厚的市场
    • 印度
      • 印度是全球最大的仿製药生产国，是推动市场增长的重要因素。
    • 澳大利亚
      • 老龄化人口的增加可能会增加澳大利亚 OAB 患者的数量——这是支持该市场增长的关键因素
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
      • 在国内增加使用膀胱过度活动症药物以促进市场增长
    • 墨西哥
      • 提高 OAB 的渗透率以推动墨西哥市场的增长
    • 其他拉丁美洲
  • 中东和非洲
    • 提高中东地区的知名度可能会推动中东和非洲市场的增长

第 9 章竞争态势

  • 简介
  • 关键球员采用的获胜方法
  • 市场份额分析
  • 收入分析
  • 公司评价象限
    • 星星
    • 新兴领导者
    • 无所不在的播放器
    • 参与者
  • 前 20 名玩家的竞争基准测试
    • 公司足迹(20 家公司)
    • 公司产品足迹(20 家公司)
    • 公司的区域足迹(20 家公司)
  • 公司评价象限：初创公司/中小企业
    • 进步公司
    • 起始块
    • 响应式公司
    • 充满活力的公司
    • 竞争基准/SME Player 竞争基准
  • 竞争场景和趋势
    • 产品发布和批准
    • 交易

第 10 章公司简介

  • KEY PLAYERS
    • ASTELLAS PHARMA INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • PFIZER INC.
    • ABBVIE INC.
    • VIATRIS INC.
    • HISAMITSU PHARMACEUTICAL CO., INC.
    • JOHNSON & JOHNSON SERVICES, INC.
    • ENDO PHARMACEUTICALS INC.
    • LUPIN
    • AMNEAL PHARMACEUTICALS LLC
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • GLENMARK
    • MACLEODS PHARMACEUTICALS LTD.
    • MEDTRONIC
    • AJANTA PHARMA
    • GRANULES INDIA LIMITED
  • OTHER PLAYERS
    • UROVANT SCIENCES
    • APOTEX INC.
    • LABORIE
    • INTAS PHARMACEUTICALS LTD.
    • BAYER AG
    • MEDYTOX
    • ALTHERX PHARMACEUTICALS
    • TAIHO PHARMACEUTICAL CO., LTD.
    • HUGEL, INC.

第 11 章附录

简介目录
Product Code: PH 5449

The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% during the forecast period. Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have significant positive impact.

"Mirabergon segment dominates the overactive bladder (OAB) treatment market in 2021."

Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.

"The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period."

Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.

"North America held dominant share in 2021."

Geographically, the overactive bladder (OAB) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Supply Side: 80.0%, Demand Side: 20.0%
  • By Designation - Managers: 45.0%, CXOs & Directors:30.0%, Excecutives:25.0%
  • By Region - North America: 55%, Europe: 20%, Asia Pacific: 10%, Latin America: 10%, and the Middle East and Africa: 5%

List of Companies Profiled in the Report

    • Astellas Pharma Inc. (Japan)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Pfizer Inc. (US)
    • Abbvie Inc. (US)
    • Viatris Inc. (US)
    • Hisamitsu Pharmaceutical Co., Inc. (Japan)
    • Johnson & Johnson Services, Inc. (US)
    • Endo Pharmaceuticals Inc. (Ireland)
    • Lupin (India)
    • Amneal Pharmaceuticals Llc (US)
    • Sun Pharmaceutical Industries Ltd. (India)
    • Glenmark (India)
    • Macleods Pharmaceuticals Ltd (India)
    • Medtronic (Ireland)
    • Ajanta Pharma (India)
    • Granules India Limited (India)
    • Urovant Sciences (US)
    • Apotex Inc. (Canada)
    • Laborie (US)
    • Intas Pharmaceuticals Ltd. (India)
    • Bayer Ag (Germany)
    • Medytox (South Korea)
    • Altherx Pharmaceuticals (US)
    • Taiho Pharmaceutical Co., Ltd. (Japan)
    • Hugel, Inc. (South Korea)

Research Coverage:

This report provides a detailed picture of the global overactive bladder treatment market. It aims at estimating the size and future growth potential of the market across different segments, such as type, disease type and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell analysis market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on cell analysis offered by the top 25 players in the cell analysis market. The report analyses the overactive bladder treatment market by type, disease type and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various cell analysis across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the overactive bladder (OAB) treatment market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the overactive bladder treatment market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 PRIMARY RESEARCH
    • FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
    • 2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
    • FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
  • 2.2 DATA TRIANGULATION APPROACH
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
    • 2.2.1 SECONDARY RESEARCH
    • 2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
  • 2.3 RESEARCH LIMITATIONS
  • 2.4 RISK ASSESSMENT
  • 2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • 2.5.1 SUPPLY SIDE
    • 2.5.2 DEMAND SIDE
      • 2.5.2.1 Insights from primary experts

3 EXECUTIVE SUMMARY

    • FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE BLADDER TREATMENT MARKET

4 PREMIUM INSIGHTS

  • 4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
    • FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
  • 4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)
    • FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
  • 4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
    • FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2027
  • 4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Rising prevalence of overactive bladder syndrome
      • 5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
    • FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
      • 5.2.1.3 Development and use of innovative intravesical therapies
      • 5.2.1.4 Growing R&D investments and the launch of novel therapies in the coming years
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Frequent product recalls
      • 5.2.2.2 Increased side effects of anticholinergic drugs
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Social stigma and lack of awareness about OAB
  • 5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET
    • FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 18 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
    • FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
  • 5.9 REGULATORY SCENARIO
    • 5.9.1 PHARMACEUTICAL INDUSTRY
      • 5.9.1.1 Regulatory requirements
        • 5.9.1.1.1 EU regulations
        • 5.9.1.1.2 US regulations
    • 5.9.2 MEDICAL DEVICE INDUSTRY
      • 5.9.2.1 Regulatory requirements
        • 5.9.2.1.1 EU regulations
        • 5.9.2.1.2 US regulations
    • TABLE 2 LIST OF REGULATORY AUTHORITIES
  • 5.10 TECHNOLOGY ANALYSIS
  • 5.11 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.12 PATENT ANALYSIS
    • FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
    • TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 THREAT FROM NEW ENTRANTS
    • 5.13.2 THREAT FROM SUBSTITUTES
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 BARGAINING POWER OF SUPPLIERS
    • 5.13.5 DEGREE OF COMPETITION
  • 5.14 PRICING ANALYSIS
    • TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS (GENERICS)
    • TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
    • TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS
    • FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
  • 5.16 PIPELINE ANALYSIS
    • FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS

6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.2 MIRABEGRON
    • 6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
    • TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 ANTICHOLINERGICS
    • TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • 6.3.1 SOLIFENACIN
      • 6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence-a key factor driving market growth
    • TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 OXYBUTYNIN
      • 6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
    • TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.3 FESOTERODINE
      • 6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
    • TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.4 DARIFENACIN
      • 6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
    • TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.5 TOLTERODINE
      • 6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy
    • TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.6 TROSPIUM
      • 6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
    • TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.7 OTHER ANTICHOLINERGICS
    • TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 BOTOX
    • 6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
    • TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2020-2027 (USD MILLION)
  • 6.5 NEUROMODULATION
    • 6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
    • TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION, BY REGION, 2020-2027 (USD MILLION)
  • 6.6 OTHER TREATMENTS
    • TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS, BY REGION, 2020-2027 (USD MILLION)

7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE

  • 7.1 INTRODUCTION
    • TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • 7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
    • 7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
    • TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
    • TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 7.3.1 PARKINSON'S DISEASE
      • 7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson's disease to drive market growth
    • TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON'S DISEASE, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 STROKES
      • 7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
    • TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.3 MULTIPLE SCLEROSIS
      • 7.3.3.1 Favorable reimbursement policies to support the growth of the OAB treatment market for MS
    • TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.4 SPINAL CORD INJURIES
      • 7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
    • TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.5 OTHER DISORDERS
    • TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020-2027 (USD MILLION)

8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
    • TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
    • TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada
    • TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
    • TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.2 UK
      • 8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth in the OAB market
    • TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
    • TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
    • TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
    • TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
    • TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
    • TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
    • TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.1 JAPAN
      • 8.4.1.1 Advancements in treatment options to fuel growth in the market in Japan
    • TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
    • TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 India is the world's largest producer of generic drugs- a key factor driving market growth
    • TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.4 AUSTRALIA
      • 8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia-a major factor supporting the growth of this market
    • TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.5 REST OF ASIA PACIFIC
    • TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.5 LATIN AMERICA
    • TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.5.1 BRAZIL
      • 8.5.1.1 Increased use of overactive bladder drugs in the country to drive growth in the market
    • FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004-2050
    • TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.5.2 MEXICO
      • 8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
    • TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.5.3 REST OF LATIN AMERICA
    • TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA
    • TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
  • 9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
    • TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION
  • 9.4 REVENUE ANALYSIS
    • FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
  • 9.5 COMPANY EVALUATION QUADRANT
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
    • FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2021
  • 9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
    • 9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
    • TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
    • 9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
    • TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
    • 9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
    • TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • 9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 9.7.1 PROGRESSIVE COMPANIES
    • 9.7.2 STARTING BLOCKS
    • 9.7.3 RESPONSIVE COMPANIES
    • 9.7.4 DYNAMIC COMPANIES
    • FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
    • 9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
  • 9.8 COMPETITIVE SCENARIO AND TRENDS
    • 9.8.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-MAY 2022
    • 9.8.2 DEALS
    • TABLE 131 DEALS, JANUARY 2019-MAY 2022

10 COMPANY PROFILES

  • 10.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 ASTELLAS PHARMA INC.
    • TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
    • FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
    • 10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
    • FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
    • 10.1.3 PFIZER INC.
    • TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
    • FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
    • 10.1.4 ABBVIE INC.
    • TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
    • FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
    • 10.1.5 VIATRIS INC.
    • TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
    • FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
    • 10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
    • TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
    • FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
    • 10.1.7 JOHNSON & JOHNSON SERVICES, INC.
    • TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
    • FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
    • 10.1.8 ENDO PHARMACEUTICALS INC.
    • TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
    • FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
    • 10.1.9 LUPIN
    • TABLE 140 LUPIN: BUSINESS OVERVIEW
    • FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
    • 10.1.10 AMNEAL PHARMACEUTICALS LLC
    • TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
    • FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
    • 10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
    • FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
    • 10.1.12 GLENMARK
    • TABLE 143 GLENMARK: BUSINESS OVERVIEW
    • FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
    • 10.1.13 MACLEODS PHARMACEUTICALS LTD.
    • TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
    • FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
    • 10.1.14 MEDTRONIC
    • TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
    • FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
    • 10.1.15 AJANTA PHARMA
    • TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
    • FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
    • 10.1.16 GRANULES INDIA LIMITED
    • TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
    • FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)
  • 10.2 OTHER PLAYERS
    • 10.2.1 UROVANT SCIENCES
    • TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
    • 10.2.2 APOTEX INC.
    • TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
    • 10.2.3 LABORIE
    • TABLE 150 LABORIE: BUSINESS OVERVIEW
    • 10.2.4 INTAS PHARMACEUTICALS LTD.
    • TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
    • 10.2.5 BAYER AG
    • TABLE 152 BAYER AG: BUSINESS OVERVIEW
    • 10.2.6 MEDYTOX
    • TABLE 153 MEDYTOX: BUSINESS OVERVIEW
    • 10.2.7 ALTHERX PHARMACEUTICALS
    • TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
    • 10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
    • TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
    • 10.2.9 HUGEL, INC.
    • TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS